Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
FDA approval of Mounjaro (tirzepatide) injection, the first once-weekly GIP and GLP-1 receptor agonist approved to improve blood sugar control in adults with type 2 diabetes
However, the review rated the overall evidence quality as very low due to small sample sizes, short follow-up periods, high risk of bias, and predominantly manufacturer-funded studies
When tested as a once-daily injection in single and multiple doses varying up to 0.18 mg in healthy normal to overweight volunteers, gastrointestinal adverse events (nausea, diarrhoea, constipation, vomiting) were encountered, but the drug was described as well tolerated
And guessing with a compound as potent as tirzepatide, which acts on both GLP-1 and GIP receptors simultaneously, is a risk nobody should take
In the U.S., Wegovy tablets are FDA-approved for chronic weight management
